GT Biopharma (GTBP) Stock gains Momentum After Analyst’s Note

GT Biopharma Inc (NASDAQ:GTBP) stock is trading higher by about 1% in pre-market trading after H.C. Wainwright initiated coverage on the stock with a Buy rating and set a price target of $25 – a potential gain of 74% from Friday’s closing price.

GT Biopharma (GTBP) Stock gains Momentum After Analyst’s Note

H.C. Wainwright initiates GTBP with a Buy and price target of $25. Analyst Robert Burns said, “The company has developed both TriKEs and tetra-specific NK cell engagers, or TetraKEs. These molecules aim to drive interactions between NK cells and tumor cells, forming an immune synapse between these two cell types and thereby inducing NK cell activation at that site. NK cells mediate antibody-dependent cell-mediated cytotoxicity (ADCC) through the highly potent CD16 activating receptor.

Related:  Healthier Choices Management (HCMC) Stock Review: Here is The Trade Plan

In our view, GT Biopharma’s proprietary product candidates have the potential to overcome certain limitations of CAR-T therapy, emerging cell-based immunotherapy approaches and other antibody therapies. Unlike full-length tri-specific antibodies, TriKEs and TetraKEs are small single-chain fusion proteins that bind the CD16 receptor of NK cells directly, inducing more potent and durable responses as seen in preclinical experiments.

These molecules also have superior biodistribution as a consequence of their smaller size, which may prove crucial in facilitating effective attacks on solid tumors that have historically been difficult to penetrate and in which CAR-T therapy has thus far failed to achieve meaningful results. In addition, TriKEs and TetraKEs are designed to be non-immunogenic, possess rapid clearance properties and can be engineered flexibly to target a variety of tumor antigens.”

Jack Dawkins

Finance and Tech Contributor